Washington: During ACR Convergence 2024, the American College of Rheumatology (ACR) unveiled a summary of the 2024 Guideline ...

ImmuneOnco Biopharmaceuticals has received approval from China’s National Medical Products Administration for a Phase II ...

Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN ...

The new guideline also recommends faster tapering to a lower dose of glucocorticoids and a longer duration of ...

Two studies presented at the 2024 American College of Rheumatology (ACR) Annual Meeting revealed that GLP-1 receptor agonists ...

A noninvasive urinary biomarker panel predicts lupus nephritis activity and response better than proteinuria, and, if further validated, may aid diagnosis and gauge treatment response, investigators ...

The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.

The ACR has released a summary of a new 2024 guideline for the screening, treatment, and management of Lupus Nephritis.

VANCOUVER, BC / / November 25, 2024 / BioNxt Solutions Inc. ('BioNxt' or the 'Company') (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce the expansion of its ...

Objective Previous studies have revealed functional changes within the cerebral hemispheres of patients with SLE; however the ...

Kidney issues: Lupus can lead to kidney inflammation, or lupus nephritis, which is a serious complication that can affect kidney function. Respiratory and cardiovascular Issues: Difficulty breathing ...